Di Lu, Yueyong Li, Ju Liao, Wenxian Lin, Xiuli Mao, Xinxin Wei, Xiaohong Qin
{"title":"表皮生长因子受体结合 P53 基因突变的非小细胞肺癌靶向治疗进展","authors":"Di Lu, Yueyong Li, Ju Liao, Wenxian Lin, Xiuli Mao, Xinxin Wei, Xiaohong Qin","doi":"10.32629/jcmr.v5i2.2316","DOIUrl":null,"url":null,"abstract":"Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer death worldwide. NSCLC patients with epidermal growth factor receptor (EGFR) mutations were treated with EGFR-tyrosine kinase inhibitor (TKI), but EGFR mutations combined with other genes had a shorter survival. However, the P53 gene mutation is a common combined mutation in patients with NSCLC with EGFR gene mutation. This review summarizes the development of targeted NSCLC for EGFR with P53 mutations.","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":" 18","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in Targeted Therapy of Non-small Cell Lung Cancer with EGFR Combined With P53 Gene Mutation\",\"authors\":\"Di Lu, Yueyong Li, Ju Liao, Wenxian Lin, Xiuli Mao, Xinxin Wei, Xiaohong Qin\",\"doi\":\"10.32629/jcmr.v5i2.2316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer death worldwide. NSCLC patients with epidermal growth factor receptor (EGFR) mutations were treated with EGFR-tyrosine kinase inhibitor (TKI), but EGFR mutations combined with other genes had a shorter survival. However, the P53 gene mutation is a common combined mutation in patients with NSCLC with EGFR gene mutation. This review summarizes the development of targeted NSCLC for EGFR with P53 mutations.\",\"PeriodicalId\":15431,\"journal\":{\"name\":\"Journal of Clinical Medicine Research\",\"volume\":\" 18\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Medicine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32629/jcmr.v5i2.2316\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32629/jcmr.v5i2.2316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Advances in Targeted Therapy of Non-small Cell Lung Cancer with EGFR Combined With P53 Gene Mutation
Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer death worldwide. NSCLC patients with epidermal growth factor receptor (EGFR) mutations were treated with EGFR-tyrosine kinase inhibitor (TKI), but EGFR mutations combined with other genes had a shorter survival. However, the P53 gene mutation is a common combined mutation in patients with NSCLC with EGFR gene mutation. This review summarizes the development of targeted NSCLC for EGFR with P53 mutations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
